| dc.creator | Gkotinakou I.-M., Mylonis I., Tsakalof A. | en |
| dc.date.accessioned | 2023-01-31T07:43:04Z | |
| dc.date.available | 2023-01-31T07:43:04Z | |
| dc.date.issued | 2022 | |
| dc.identifier | 10.3390/cancers14071791 | |
| dc.identifier.issn | 20726694 | |
| dc.identifier.uri | http://hdl.handle.net/11615/72510 | |
| dc.description.abstract | Vitamin D is a hormone that, through its action, elicits a broad spectrum of physiological responses ranging from classic to nonclassical actions such as bone morphogenesis and immune function. In parallel, many studies describe the antiproliferative, proapoptotic, antiangiogenic effects of calcitriol (the active hormonal form) that contribute to its anticancer activity. Additionally, epidemiological data signify the inverse correlation between vitamin D levels and cancer risk. On the contrary, tumors possess several adaptive mechanisms that enable them to evade the anticancer effects of calcitriol. Such maladaptive processes are often a characteristic of the cancer microenvi-ronment, which in solid tumors is frequently hypoxic and elicits the overexpression of Hypoxia-Inducible Factors (HIFs). HIF-mediated signaling not only contributes to cancer cell survival and proliferation but also confers resistance to anticancer agents. Taking into consideration that calcit-riol intertwines with signaling events elicited by the hypoxic status cells, this review examines their interplay in cellular signaling to give the opportunity to better understand their relationship in cancer development and their prospect for the treatment of cancer. © 2022 by the authors. Licensee MDPI, Basel, Switzerland. | en |
| dc.language.iso | en | en |
| dc.source | Cancers | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127434450&doi=10.3390%2fcancers14071791&partnerID=40&md5=291cd2003ff8e2f2edddc73dab2635dc | |
| dc.subject | antineoplastic agent | en |
| dc.subject | beta catenin | en |
| dc.subject | calcitriol | en |
| dc.subject | carboplatin | en |
| dc.subject | celastrol | en |
| dc.subject | cholesterol monooxygenase (side chain cleaving) | en |
| dc.subject | colecalciferol 24 hydroxylase | en |
| dc.subject | docetaxel | en |
| dc.subject | flavonoid | en |
| dc.subject | hypoxia inducible factor | en |
| dc.subject | hypoxia inducible factor 1alpha | en |
| dc.subject | hypoxia inducible factor 2alpha | en |
| dc.subject | mitogen activated protein kinase 1 | en |
| dc.subject | mitogen activated protein kinase 3 | en |
| dc.subject | natural product | en |
| dc.subject | pt2385 | en |
| dc.subject | pt2399 | en |
| dc.subject | resveratrol | en |
| dc.subject | retinoid X receptor | en |
| dc.subject | STAT3 protein | en |
| dc.subject | unclassified drug | en |
| dc.subject | vasculotropin | en |
| dc.subject | vitamin D | en |
| dc.subject | vitamin D binding protein | en |
| dc.subject | vitamin D receptor | en |
| dc.subject | von Hippel Lindau protein | en |
| dc.subject | carcinogenesis | en |
| dc.subject | clear cell renal cell carcinoma | en |
| dc.subject | hormonal regulation | en |
| dc.subject | human | en |
| dc.subject | MAPK signaling | en |
| dc.subject | metastasis | en |
| dc.subject | multiple cycle treatment | en |
| dc.subject | nonhuman | en |
| dc.subject | Pi3K/Akt signaling | en |
| dc.subject | prostate cancer | en |
| dc.subject | Review | en |
| dc.subject | solid malignant neoplasm | en |
| dc.subject | transcription regulation | en |
| dc.subject | tumor hypoxia | en |
| dc.subject | tumor microenvironment | en |
| dc.subject | ultraviolet B radiation | en |
| dc.subject | unspecified side effect | en |
| dc.subject | vitamin D responsive element | en |
| dc.subject | vitamin metabolism | en |
| dc.subject | Wnt signaling | en |
| dc.subject | MDPI | en |
| dc.title | Vitamin D and Hypoxia: Points of Interplay in Cancer | en |
| dc.type | other | en |